Research programme: HIV integrase inhibitors - Inhibitex

Drug Profile

Research programme: HIV integrase inhibitors - Inhibitex

Alternative Names: INH-001; INH-I001

Latest Information Update: 17 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Georgia
  • Developer Inhibitex
  • Class
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended HIV infections

Most Recent Events

  • 14 Feb 2012 Inhibitex has been acquired by Bristol-Myers Squibb
  • 12 May 2009 Suspended - Preclinical for HIV infections in USA (PO)
  • 19 Sep 2007 Preclinical trials in HIV infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top